These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 9398202)

  • 1. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM; Whitehead JP; Raju NL; Lippard SJ
    Biochemistry; 1997 Dec; 36(48):14807-15. PubMed ID: 9398202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE; Zamble DB; Lippard SJ; Essigmann JM
    Biochemistry; 1998 Jan; 37(1):352-62. PubMed ID: 9425057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM; Whitehead JP; Lippard SJ
    Biochemistry; 1996 May; 35(19):6089-99. PubMed ID: 8634251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM; Rould MA; He Q; Pabo CO; Lippard SJ
    Nature; 1999 Jun; 399(6737):708-12. PubMed ID: 10385126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA sequence context and protein composition modulate HMG-domain protein recognition of cisplatin-modified DNA.
    Dunham SU; Lippard SJ
    Biochemistry; 1997 Sep; 36(38):11428-36. PubMed ID: 9298962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nature of full-length HMGB1 binding to cisplatin-modified DNA.
    Jung Y; Lippard SJ
    Biochemistry; 2003 Mar; 42(9):2664-71. PubMed ID: 12614161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single HMG domain in high-mobility group 1 protein binds to DNAs as small as 20 base pairs containing the major cisplatin adduct.
    Chow CS; Barnes CM; Lippard SJ
    Biochemistry; 1995 Mar; 34(9):2956-64. PubMed ID: 7893709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Photoreactivity of platinum(II) in cisplatin-modified DNA affords specific cross-links to HMG domain proteins.
    Kane SA; Lippard SJ
    Biochemistry; 1996 Feb; 35(7):2180-8. PubMed ID: 8652559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X; Beckmann H; Jantzen HM; Essigmann JM
    Biochemistry; 1998 Nov; 37(46):16307-15. PubMed ID: 9819223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction between cisplatin-modified DNA and the HMG boxes of HMG 1: DNase I footprinting and circular dichroism.
    Locker D; Decoville M; Maurizot JC; Bianchi ME; Leng M
    J Mol Biol; 1995 Feb; 246(2):243-7. PubMed ID: 7869375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LEF-1 recognition of platinated GG sequences within double-stranded DNA. Influence of flanking bases.
    Chválová K; Sari MA; Bombard S; Kozelka J
    J Inorg Biochem; 2008 Feb; 102(2):242-50. PubMed ID: 17961652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA sequence context modulates the impact of a cisplatin 1,2-d(GpG) intrastrand cross-link on the conformational and thermodynamic properties of duplex DNA.
    Pilch DS; Dunham SU; Jamieson ER; Lippard SJ; Breslauer KJ
    J Mol Biol; 2000 Feb; 296(3):803-12. PubMed ID: 10677282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human replication protein A preferentially binds cisplatin-damaged duplex DNA in vitro.
    Patrick SM; Turchi JJ
    Biochemistry; 1998 Jun; 37(24):8808-15. PubMed ID: 9628743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin-DNA binding specificity of calf high-mobility group 1 protein.
    Turchi JJ; Li M; Henkels KM
    Biochemistry; 1996 Mar; 35(9):2992-3000. PubMed ID: 8608137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of DNA interstrand cross-link of antitumor cisplatin by HMGB1 protein.
    Kasparkova J; Delalande O; Stros M; Elizondo-Riojas MA; Vojtiskova M; Kozelka J; Brabec V
    Biochemistry; 2003 Feb; 42(5):1234-44. PubMed ID: 12564926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HMG-domain protein recognition of cisplatin 1,2-intrastrand d(GpG) cross-links in purine-rich sequence contexts.
    Cohen SM; Mikata Y; He Q; Lippard SJ
    Biochemistry; 2000 Sep; 39(38):11771-6. PubMed ID: 10995245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts.
    Vaisman A; Lim SE; Patrick SM; Copeland WC; Hinkle DC; Turchi JJ; Chaney SG
    Biochemistry; 1999 Aug; 38(34):11026-39. PubMed ID: 10460158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
    Takahara PM; Rosenzweig AC; Frederick CA; Lippard SJ
    Nature; 1995 Oct; 377(6550):649-52. PubMed ID: 7566180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recognition of platinum-induced DNA damage by nuclear proteins: screening for mechanisms.
    Marples B; Adomat H; Billings PC; Farrell NP; Koch CJ; Skov KA
    Anticancer Drug Des; 1994 Oct; 9(5):389-99. PubMed ID: 7945723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
    Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.